1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
/Biogen%20logo%20is%20seen%20at%20its%20headquarters%20in%20Cambridge%2C%20Massachusetts%20By%20Tada%20Images.jpeg)
Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.
1 S&P 500 Stock with Promising Prospects and 2 We Question
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline...
NEW YORK , June 25, 2026 /PRNewswire/ --Â Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
NEW YORK , June 18, 2026 /PRNewswire/ --Â Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...